Financement of Pierre Fabre group pharmaceutical R&D programs in France.
Objectives
The Pierre Fabre group has R&D activities in several therapeutic areas: Oncology, Central Nervous System, Cardio-vascular, Immunology and Dermatology. The group develops, manufactures and markets pharmaceutical products and services that make a significant difference to patients in terms of health, quality of life and in terms of lower medical costs for public healthcare systems.
Comments
The project will be financed under The Risk Sharing Finance Facility (RSFF), an innovative credit risk sharing scheme jointly set up by the European Commission and the European Investment Bank to improve access to debt financing for private companies or public institutions promoting activities with a higher financial risk profile in the fields of research, technological development, demonstration and innovation investments.
The activities are monitored by the group’s internal control department, to verify compliance with the ISO 14000 standards on environmental management. Competent national authorities and the European Medical Agency (EMA) frequently inspect the sites concerned by the project, to check compliance with the relevant environmental and health regulations.
Procurement
Previous operations with the promoter have demonstrated that international enquiry amongst short-listed, specialist laboratory and pilot scale equipment suppliers are used. The promoter is a private company, not operating in the Utilities sector and therefore not covered by EU Directives on procurement. Procedures followed are in the best interest of the project and satisfactory to the Bank.
Status
Signed
-
18/11/2011.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities. Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
The EIB is committed to achieving the highest possible level of transparency. The EIB Transparency Policy sets out how the EIB discloses information and consults with its stakeholders so as to promote better awareness and understanding of its strategies, policies and operations.
The project will be financed under The Risk Sharing Finance Facility (RSFF), an innovative credit risk sharing scheme jointly set up by the European Commission and the European Investment Bank to improve access to debt financing for private companies or public institutions promoting activities with a higher financial risk profile in the fields of research, technological development, demonstration and innovation investments.